# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

# B. Purpose for Submission:

Notification of intent to manufacture and market a group of reagents and their associated controls and calibrators for use on the ABX PENTRA 400

# C. Measurand:

Alkaline Phosphatase, Creatinine, Calcium, $\mathrm { C O } _ { 2 }$ , Iron, Magnesium, Phosphorus, Urea, Uric Acid

# D. Type of Test:

# E. Applicant:

Horiba ABX

# F. Proprietary and Established Names:

Trade/Proprietary Name: Common or Usual Name:

ABX PENTRA ALP CP ALP - Alkaline phosphatase

Trade/Proprietary Name: Common or Usual Name:

ABX PENTRA Calcium CP Calcium

Trade/Proprietary Name: Common or Usual Name:

ABX PENTRA CO2 RTU Carbon Dioxide

Trade/Proprietary Name: Common or Usual Name:

ABX PENTRA Creatinine CP Creatinine

Trade/Proprietary Name: Common or Usual Name:

ABX PENTRA Iron CP Iron

Trade/Proprietary Name: Common or Usual Name:

ABX PENTRA Magnesium RTU Magnesium

Trade/Proprietary Name: Common or Usual Name:

ABX PENTRA Phosphorus CP Phosphorus

Trade/Proprietary Name: Common or Usual Name:

ABX PENTRA Urea CP Urea

Trade/Proprietary Name: Common or Usual Name:

ABX PENTRA Uric Acid CP Uric Acid

Trade/Proprietary Name: Common or Usual Name:

ABX PENTRA CO2 ControlCO2 Control

Trade/Proprietary Name: Common or Usual Name:

ABX PENTRA CO2 Cal $\mathrm { C O } _ { 2 }$ Calibrator

# G. Regulatory Information:

1. Regulation section:

21 CFR 862.1050: Alkaline phosphatase Test System   
21 CFR 862.1145: Calcium Test System   
21 CFR 862.1160: Bicarbonate/carbon dioxide Test System   
21 CFR 862.1225: Creatinine Test System   
21 CFR 862.1410: Iron (non-heme) Test System   
21 CFR 862.1495: Magnesium Test System   
21 CFR 862.1580: Phosphorus (inorganic) Test System   
21 CFR 862.1770: Urea nitrogen Test System   
21 CFR 862.1775: Uric acid Test System   
21 CFR 862.1660: Quality control material (assayed and unassayed)   
21 CFR 862.1150: Calibrator

# 2. Classification:

Class II - Alkaline phosphatase, Calcium, $\mathrm { C O } _ { 2 }$ RTU, Creatinine, Magnesium, Phosphorus, Urea, Calibrators

Class I, reserved - Iron, Uric Acid, Controls

3. Product code:

Alkaline phosphatase- CJE   
Calcium - CIC   
$\mathrm { C O } _ { 2 }$ - KHS

Creatinine - CGX Iron - JIY Magnesium - JGJ Phosphorus - CEO Urea - CDQ Uric Acid - KNK $\mathrm { C O } _ { 2 }$ Control – JJX $\mathrm { C O } _ { 2 }$ Cal - JIT

4. Panel: 75, Chemistry

# H. Intended Use:

1. Intended use(s): See indications for use below

2. Indication(s) for use:

General Chemistries reagents, with associated calibrators and controls, are intended for use on ABX PENTRA 400 Clinical Chemistry Analyzer to measure a variety of analytes.

ABX PENTRA ALP CP reagent with associated calibrators and controls are for quantitative in vitro diagnostic determination of alkaline phosphatase in human serum and plasma based on a kinetic photometric test using pNitrophenylphosphate. Measurements of alkaline phosphatase or its isoenzymes are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases.

ABX PENTRA Calcium CP reagent with associated calibrators and controls are for quantitative in vitro diagnostic determination of calcium in human serum and plasma based on a photometric test using orthocresolphtalein complexone. Calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany (intermittent muscular contractions or spasms).

ABX PENTRA $\mathbf { C O } _ { 2 }$ RTU reagent with associated calibrators and controls are for quantitative in vitro diagnostic determination of carbon dioxide in human serum and plasma based on an enzymatic test using phosphoenolpyruvate (PEP), phosphorenolpyruvate carboxylase (PEPC) and an analog of NADH. Bicarbonate/carbon measurements are used in the diagnosis and treatment of numerous potentially serious disorders associated with changes in body acid-base balance.

ABX PENTRA Creatinine CP reagent with associated calibrators and controls are for quantitative in vitro diagnostic determination of creatinine in human serum and plasma based on a kinetic method using alkaline picrate (Jaffé method). Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.

ABX PENTRA Iron CP reagent with associated calibrators and controls are for quantitative in vitro diagnostic determination of iron (non-heme) in human serum and plasma based on a photometric test (Ferene method). Iron (non-heme) measurements are used in the diagnosis and treatment of diseases such as iron deficiency anemia and hemochromatosis.

ABX PENTRA Magnesium RTU reagent with associated calibrators and controls are for quantitative in vitro diagnostic determination of magnesium in human serum and plasma based on a photometric test using xylidyl blue. Magnesium measurements are used in the diagnosis and treatment of hypomagnesemia (abnormally low plasma levels of magnesium) and hypermagnesemia (abnormally high plasma levels of magnesium).

ABX PENTRA Phosphorus CP reagent with associated calibrators and controls are for quantitative in vitro diagnostic determination of phosphorus in human serum and plasma based on a UV method using phosphomolybdate. Measurement of phosphorus (inorganic) is used in the diagnosis and treatment of various disorders, including parathyroid gland and kidney diseases, and vitamin D imbalance.

ABX PENTRA Urea CP reagent with associated calibrators and controls are for quantitative in vitro diagnostic determination of urea / urea nitrogen (an endproduct of nitrogen metabolism) in human serum and plasma based on an enzymatic UV test using urease and glutamate dehydrogenase. Measurements obtained by this device are used in the diagnosis and treatment of certain renal and metabolic diseases.

ABX PENTRA Uric Acid CP reagent with associated calibrators and controls are for quantitative in vitro diagnostic determination of uric acid in human serum and plasma based on the enzymatic determination of uric acid using a chromogenic system in the presence of peroxidase and uricase (Trinder method). Measurements obtained by this device are used in the diagnosis and treatment of numerous renal and metabolic disorders, including renal failure, gout, leukemia, psoriasis, starvation or other wasting conditions, and of patients receiving cytotoxic drugs.

The ABX PENTRA $\mathbf { C O } _ { 2 }$ Cal is a calibrator for use in the calibration of quantitative Horiba ABX PENTRA $\mathrm { C O } _ { 2 }$ RTU method on Horiba ABX clinical chemistry analyzers as specified on the vial.

The ABX PENTRA $\mathbf { C O } _ { 2 }$ Control is for use in quality control by monitoring accuracy and precision for the quantitative ABX PENTRA $\mathrm { C O } _ { 2 }$ RTU method as specified in the enclosed annex.

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: ABX PENTRA 400 Clinical Chemistry Analyzer

# I. Device Description:

The ABX PENTRA ALP CP is an in vitro diagnostic assay for the quantitative determination of alkaline phosphatase in human serum and plasma based on a kinetic photometric test using p-Nitrophenylphosphate. It is composed of a bi-reagent cassette, with $2 6 ~ \mathrm { m l }$ and $6 . 5 \mathrm { m l }$ compartments.

The ABX PENTRA Calcium CP is an in vitro diagnostic assay for the quantitative determination of calcium in human serum and plasma based on a photometric test using orthocresolphtalein complexone. It is composed of a bi-reagent cassette, with $6 6 \mathrm { m l }$ and $1 6 . 5 \mathrm { m l }$ compartments.

The ABX PENTRA Creatinine CP is an in vitro diagnostic assay for the quantitative determination of creatinine in human serum and plasma based on a kinetic method using alkaline picrate (Jaffé method). It is composed of a bi-reagent cassette, with two $2 8 ~ \mathrm { m l }$ compartments.

The ABX PENTRA Iron CP is in vitro diagnostic assay for the quantitative determination of iron (non-heme) in human serum and plasma based on a photometric test (Ferene method).It is composed of a bi-reagent cassette containing $6 9 \mathrm { m l }$ of reagent 1 and $2 0 ~ \mathrm { m l }$ of reagent 2.

The ABX PENTRA Magnesium RTU is an in vitro assay for the quantitative determination of magnesium in human serum and plasma based on a photometric test using xylidyl blue. It is composed of two identical mono-reagent vials of $2 5 ~ \mathrm { m l }$ .

The ABX PENTRA Phosphorus CP is an in vitro diagnostic assay for the quantitative determination of phosphorus in human serum and plasma based on a UV method using phosphomolybdate. It is composed of a mono-reagent cassette, with $2 9 . 5 ~ \mathrm { m l }$ compartment.

The ABX PENTRA Urea CP is an in vitro diagnostic assay for the quantitative determination of urea / urea nitrogen (an end-product of nitrogen metabolism) in human serum and plasma based on an enzymatic UV test using urease and glutamate dehydrogenase. It is composed of a bi-reagent cassette, with $6 0 ~ \mathrm { m l }$ and $1 5 ~ \mathrm { m l }$

compartments.

The ABX PENTRA Uric Acid CP is an in vitro diagnostic assay for the quantitative determination of uric acid in human serum and plasma based on the enzymatic determination of uric acid using a chromogenic system in the presence of peroxidase and uricase (Trinder method). It is composed of a bi-reagent cassette, with $6 0 \mathrm { m l }$ and $1 5 ~ \mathrm { m l }$ compartments.

The ABX PENTRA Multical is a lyophilized human serum calibrator with chemical additives and materials of biological origin. The assigned values of the calibrator components are provided in the package labeling, ensuring optimal calibration of the appropriate HORIBA ABX methods on the ABX PENTRA 400 analyzer. This calibrator is provided in ten vials of $3 ~ \mathrm { m l }$ .

The ABX PENTRA $\mathbf { C O } _ { 2 }$ RTU is an in vitro diagnostic assay for the quantitative determination of carbon dioxide in human serum and plasma based on an enzymatic test using phosphoenolpyruvate (PEP), phosphorenolpyruvate carboxylase (PEPC) and an analog of NADH. It is composed of two identical mono-reagent vials of $2 0 ~ \mathrm { m l }$

The ABX PENTRA $\mathbf { C O } _ { 2 }$ Cal is a liquid calibrator containing chemical components to be used for the calibration of the CO2 assay. The assigned value is given on the calibrator vial. This calibrator is provided in three vials of $3 ~ \mathrm { m l }$ .

The ABX PENTRA $\mathbf { C O } _ { 2 }$ Control is a liquid assayed control containing chemical components to be used for the quality control of the $\mathrm { C O } _ { 2 }$ assay. The assigned value is given in the package labeling. This control is provided in three vials of $3 ~ \mathrm { m l }$ .

# J. Substantial Equivalence Information:

1. Predicate device name(s):

<table><tr><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>ABX PENTRA ALP CP</td><td rowspan=1 colspan=1>Alkaline Phosphatase (Roche)</td></tr><tr><td rowspan=1 colspan=1>ABX PENTRA Calcium CP</td><td rowspan=1 colspan=1>Calcium (Roche)</td></tr><tr><td rowspan=1 colspan=1>ABX PENTRA CO2 RTU</td><td rowspan=1 colspan=1>CO2 Reagent (Roche)</td></tr><tr><td rowspan=1 colspan=1>ABX PENTRA Creatinine CP</td><td rowspan=1 colspan=1>Creatinine (Roche)</td></tr><tr><td rowspan=1 colspan=1>ABX PENTRA Iron CP</td><td rowspan=1 colspan=1>Raichem</td></tr><tr><td rowspan=1 colspan=1>ABX PENTRA Magnesium RTU</td><td rowspan=1 colspan=1>Reagent for Magnesium (Roche)</td></tr><tr><td rowspan=1 colspan=1>ABX PENTRA Phosphorus CP</td><td rowspan=1 colspan=1>Inorganic Phosphorus (Roche)</td></tr><tr><td rowspan=1 colspan=1>ABX PENTRA Urea CP</td><td rowspan=1 colspan=1>BUN (Roche)</td></tr><tr><td rowspan=1 colspan=1>ABX PENTRA Uric Acid CP</td><td rowspan=1 colspan=1>Uric Acid Reagent (Roche)</td></tr><tr><td rowspan=1 colspan=1>ABX PENTRA CO2 Cal</td><td rowspan=1 colspan=1>CO2 reagent standard (Roche)</td></tr><tr><td rowspan=1 colspan=1>ABX PENTRA CO2 Control</td><td rowspan=1 colspan=1>Lyphocheck assayed chemistry controlLevel 1 &amp; Level 2 (BioRad)</td></tr></table>

# 2. Predicate 510(k) number(s):

<table><tr><td rowspan=1 colspan=1>Predicate Device</td><td rowspan=1 colspan=1>510k Number</td></tr><tr><td rowspan=1 colspan=1>Alkaline Phosphatase (Roche)</td><td rowspan=1 colspan=1>k801242</td></tr><tr><td rowspan=1 colspan=1>Calcium (Roche)</td><td rowspan=1 colspan=1>k883453</td></tr><tr><td rowspan=1 colspan=1>CO2 Reagent (Roche)</td><td rowspan=1 colspan=1>k031879</td></tr><tr><td rowspan=1 colspan=1>Creatinine (Roche)</td><td rowspan=1 colspan=1>k941837</td></tr><tr><td rowspan=1 colspan=1>Iron (Raichem)</td><td rowspan=1 colspan=1>K864819</td></tr><tr><td rowspan=1 colspan=1>Magnesium (Roche)</td><td rowspan=1 colspan=1>k901758</td></tr><tr><td rowspan=1 colspan=1>Inorganic Phosphorus (Roche)</td><td rowspan=1 colspan=1>k891475</td></tr><tr><td rowspan=1 colspan=1>BUN (Roche)</td><td rowspan=1 colspan=1>k 954000</td></tr><tr><td rowspan=1 colspan=1>Uric Acid (Roche)</td><td rowspan=1 colspan=1>K922762</td></tr><tr><td rowspan=1 colspan=1>CO2 reagent standard (Roche)</td><td rowspan=1 colspan=1>k 031879</td></tr><tr><td rowspan=1 colspan=1>Lyphocheck assayed chemistry controlLevel 1 &amp; Level 2 (BioRad)</td><td rowspan=1 colspan=1>k 891475</td></tr></table>

# 3. Comparison with predicate:

ABX PENTRA ALP CP:   

<table><tr><td rowspan=1 colspan=1>cYanmaGellowb</td><td rowspan=1 colspan=1>Predicate device (K801242):</td><td rowspan=1 colspan=1>Device :</td></tr><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>Alkaline Phosphatase</td><td rowspan=1 colspan=1>ABX Pentra ALP CP</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>Alkaline phosphatase</td><td rowspan=1 colspan=1>Alkaline phosphatase</td></tr><tr><td rowspan=1 colspan=1>Method :</td><td rowspan=1 colspan=1>Kinetic photometric test usingnitrophenylphosphate</td><td rowspan=1 colspan=1>Identical</td></tr><tr><td rowspan=1 colspan=1>Specimen :</td><td rowspan=1 colspan=1>SerumPlasma</td><td rowspan=1 colspan=1>SerumPlasma</td></tr><tr><td rowspan=1 colspan=1>Component reagentmatrices</td><td rowspan=1 colspan=1>Single-reagent bottles,lyophilized:REAGENT : 2-Amino-2-methyl-1,3-propanediol(AMPD), magnesium salt,zinc sulphate, N-(2-Hydroxyethyl)ethylenediaminetriacetic acid (HEDTA), 4-Nitrophenylphosphate,buffers, stabilizers and fillers</td><td rowspan=1 colspan=1>Bi-reagent cassette, ready touse:REAGENT 1 : 2-Amino-2-methyl-1-propanol,magnesium sulphate, zincsulphate, sodium azideREAGENT 2 : p-Nitrophenylphosphate,sodium azide</td></tr></table>

ABX Pentra Calcium CP:   

<table><tr><td colspan="1" rowspan="1">cYanmaGYellowb</td><td colspan="1" rowspan="1">Predicate device (K883453):</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">Calcium</td><td colspan="1" rowspan="1">ABX Pentra Calcium CP</td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Calcium</td><td colspan="1" rowspan="1">Calcium</td></tr><tr><td colspan="1" rowspan="1">Method :</td><td colspan="1" rowspan="1">Photometric test usingAsenazo III</td><td colspan="1" rowspan="1">Photometric test using ortho-cresolphtalein complexone(OPC)</td></tr><tr><td colspan="1" rowspan="1">Specimen :</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">SerumPlasma</td></tr><tr><td colspan="1" rowspan="1">cYanmaGellowb</td><td colspan="1" rowspan="1">Predicate device (K883453):</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">Calcium</td><td colspan="1" rowspan="1">ABX Pentra Calcium CP</td></tr><tr><td colspan="1" rowspan="1">Component reagentmatrices</td><td colspan="1" rowspan="1">Single reagent bottles:REAGENT : Arsenazo III,buffers, stabilizers, fillers</td><td colspan="1" rowspan="1">Bi-reagent cassette, ready touseREAGENT 1 : Ethanolamine,DetergentsREAGENT 2 : 0-Cresolphtalein complexone,8-Hydroxyquinoline,Hydrochloric acid</td></tr><tr><td colspan="1" rowspan="1">Packaging</td><td colspan="1" rowspan="1">Kit composed of single-reagent bottlesREAGENT : 2 x 120 ml</td><td colspan="1" rowspan="1">Bi-reagent cassette :REAGENT 1 : 66 mlREAGENT 2 : 16.5 ml</td></tr></table>

ABX Pentra $\underline { { \mathbf { C } \mathbf { O } _ { 2 } } }$ RTU:   

<table><tr><td rowspan=1 colspan=1>cYanmaGellob</td><td rowspan=1 colspan=1>Predicate device (K031879):</td><td rowspan=1 colspan=1>Device :</td></tr><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>CO2 Reagent</td><td rowspan=1 colspan=1>ABX Pentra CO2 RTU</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>Carbon dioxide</td><td rowspan=1 colspan=1>Carbon dioxide</td></tr><tr><td rowspan=1 colspan=1>Method :</td><td rowspan=1 colspan=1>Enzymatic test usingphosphoenolpyruvate (PEP),phosphoenolpyruvatecarboxylase (PEPC) andNADH as cofactor</td><td rowspan=1 colspan=1>Enzymatic test usingphosphoenolpyruvate (PEP),phosphoenolpyruvatecarboxylase (PEPC) and ananalog of NADH as cofactor</td></tr><tr><td rowspan=1 colspan=1>Specimen :</td><td rowspan=1 colspan=1>SerumPlasma</td><td rowspan=1 colspan=1>SerumPlasma</td></tr><tr><td rowspan=1 colspan=1>Component reagentmatrices</td><td rowspan=1 colspan=1>Single reagent bottle,lyophilized:CO2 REAGENT : PEP, NAD(reduced), MDH, PEPC,buffers, stabilizers and fillers</td><td rowspan=1 colspan=1>Single reagent bottle, ready touseREAGENT : Buffer, PEP,PEPC, MDH, NADH analog,activators, stabilizers,surfactant, preservative</td></tr></table>

ABX Pentra Creatinine CP:   

<table><tr><td colspan="1" rowspan="1">cYanmaGYellowb</td><td colspan="1" rowspan="1">Predicate device (K941837):</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">ABX Pentra Creatinine CP</td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">Creatinine</td></tr><tr><td colspan="1" rowspan="1">Method :</td><td colspan="1" rowspan="1">Kinetic method using alkalinepicrate (modification of theJaffé reaction)</td><td colspan="1" rowspan="1">Kinetic method using alkalinepicrate (modification of theJaffé reaction)</td></tr><tr><td colspan="1" rowspan="1">Specimen :</td><td colspan="1" rowspan="1">SerumPlasmaUrine</td><td colspan="1" rowspan="1">SerumPlasma</td></tr><tr><td colspan="1" rowspan="1">Component reagentmatrices</td><td colspan="1" rowspan="1">Kit composed of:REAGENT 1 : Sodium</td><td colspan="1" rowspan="1">Bi-reagent cassette, ready touse</td></tr><tr><td colspan="1" rowspan="1">cYanmaGellowb</td><td colspan="1" rowspan="1">Predicate device (K941837):</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">ABX Pentra Creatinine CP</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">borate, stabilizersREAGENT 2 : Picric acid,Sodium borate, stabilizers</td><td colspan="1" rowspan="1">REAGENT 1 : Picric acidREAGENT 2 : Sodiumhydroxide, Disodiumphosphate</td></tr></table>

ABX Pentra Iron CP:   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Predicate device (K864819):</td><td rowspan=1 colspan=1>Device :</td></tr><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>Iron</td><td rowspan=1 colspan=1>ABX Pentra Iron CP</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>Iron</td><td rowspan=1 colspan=1>Iron</td></tr><tr><td rowspan=1 colspan=1>Method :</td><td rowspan=1 colspan=1>Colorimetric measurement ofiron is performed by releasingthe protein bound iron fromits carrier protein transferrinand complexing the releasediron with a suitablechromogen. In this methodthe sample is added to anacidic buffered reagentcontaining hydroxylamine,thiourea and ferene®</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen :</td><td rowspan=1 colspan=1>SerumPlasma</td><td rowspan=1 colspan=1>SerumPlasma</td></tr><tr><td rowspan=1 colspan=1>Component reagentmatrices</td><td rowspan=1 colspan=1>acidic buffered reagentcontaining hydroxylamine,thiourea and ferene®</td><td rowspan=1 colspan=1>acidic buffered reagentcontaining hydroxylamine,thiourea and ferene®</td></tr></table>

ABX Pentra Magnesium RTU:   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Predicate device (K901758):</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">Reagent for Magnesium</td><td colspan="1" rowspan="1">ABX Pentra MagnesiumRTU</td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Magnesium</td><td colspan="1" rowspan="1">Magnesium</td></tr><tr><td colspan="1" rowspan="1">Method :</td><td colspan="1" rowspan="1">Photometric test usingChlorophosphonazo III</td><td colspan="1" rowspan="1">Photometric test using xylidylblue</td></tr><tr><td colspan="1" rowspan="1">Specimen :</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">SerumPlasma</td></tr><tr><td colspan="1" rowspan="1">Component reagentmatrices</td><td colspan="1" rowspan="1">Kit composed of:REAGENT 1 :Chlorophosphonazo III, N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid,Ethylenebis(oxyethylenenitril0)tetra acetic acid (EGTA),surfactant, preservatives</td><td colspan="1" rowspan="1">Single-reagent bottle, ready touseREAGENT : Ethanolamine,GEDTA, Xylidyl blue,detergents</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">REAGENT 2 :Ethylenedaminetetraaceticacid, N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid,surfactant, preservatives</td><td colspan="1" rowspan="1"></td></tr></table>

ABX Pentra Phosphorus CP:   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Predicate device (K883962):</td><td rowspan=1 colspan=1>Device :</td></tr><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>Inorganic Phosphorus</td><td rowspan=1 colspan=1>ABX Pentra Phosphorus CP</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>Phosphorus</td><td rowspan=1 colspan=1>Phosphorus</td></tr><tr><td rowspan=1 colspan=1>Method :</td><td rowspan=1 colspan=1>UV method usingphosphomolybdate</td><td rowspan=1 colspan=1>Identical method : UVmethod usingphosphomolybdate</td></tr><tr><td rowspan=1 colspan=1>Specimen :</td><td rowspan=1 colspan=1>SerumUrine</td><td rowspan=1 colspan=1>SerumPlasma</td></tr><tr><td rowspan=1 colspan=1>Component reagentmatrices</td><td rowspan=1 colspan=1>Single reagent bottles, readyto useREAGENT : Ammoniummolybdate, surfactants,buffers, stabilizers, fillers</td><td rowspan=1 colspan=1>Mono-reagent cassette, readyto useREAGENT : Sulfuric acid,Ammonium molybdate</td></tr></table>

ABX Pentra Urea CP:   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Predicate device (K954000):</td><td rowspan=1 colspan=1>Device :</td></tr><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>BUN</td><td rowspan=1 colspan=1>ABX Pentra Urea CP</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>Blood Urea Nitrogen (BUN)</td><td rowspan=1 colspan=1>Urea / Blood Urea Nitrogen(BUN)</td></tr><tr><td rowspan=1 colspan=1>Method :</td><td rowspan=1 colspan=1>Enzymatic UV test : &quot;Urease Glutamate Dehydrogenase&quot;</td><td rowspan=1 colspan=1>Identical (Enzymatic UV test: &quot;Urease - GlutamateDehydrogenase&quot;)</td></tr><tr><td rowspan=1 colspan=1>Specimen :</td><td rowspan=1 colspan=1>SerumPlasma</td><td rowspan=1 colspan=1>SerumPlasma</td></tr><tr><td rowspan=1 colspan=1>Component reagentmatrices</td><td rowspan=1 colspan=1>Single-reagent bottle, ready touse:REAGENT : Alpha-ketoglutarate, Urease, GLDH,Adenosine diphosphate,NADH, Sodium azide, buffer,preservative, stabilizers</td><td rowspan=1 colspan=1>Bi-reagent cassette, ready touseREAGENT 1 : TRIS, 2-Oxoglutarate, ADP, Urease,GLDH (Glutamatedehydrogenase), SodiumazideREAGENT 2 : NADH,Sodium azide</td></tr></table>

ABX Pentra Uric Acid CP:   

<table><tr><td rowspan=1 colspan=1>cYanmaGellob</td><td rowspan=1 colspan=1>Predicate device (K922762):</td><td rowspan=1 colspan=1>Device :</td></tr><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>Uric Acid</td><td rowspan=1 colspan=1>ABX Pentra Uric Acid CP</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>Uric Acid</td><td rowspan=1 colspan=1>Uric Acid</td></tr><tr><td rowspan=1 colspan=1>Method :</td><td rowspan=1 colspan=1>A modification of theenzymatic determination ofuric acid using a chromogenicsystem in the presence ofperoxidase and uricase(Trinder method)</td><td rowspan=1 colspan=1>A modification of theenzymatic determination ofuric acid using a chromogenicsystem in the presence ofperoxidase and uricase(Trinder method)</td></tr><tr><td rowspan=1 colspan=1>Specimen :</td><td rowspan=1 colspan=1>SerumPlasma</td><td rowspan=1 colspan=1>SerumPlasma</td></tr><tr><td rowspan=1 colspan=1>Component reagentmatrices</td><td rowspan=1 colspan=1>Two reagent bottles R1 andR2 containing Buffers anduricase (R1) and Peroxidasewith stabilizing buffers (R2)</td><td rowspan=1 colspan=1>It is composed of a bi-reagentcassette, with 60 ml and 15 mlcompartments containingBuffers and uricase (R1) andPeroxidase with stabilizingbuffers (R2)</td></tr></table>

ABX Pentra CO2 Cal:   

<table><tr><td></td><td>Predicate device (K031879):</td><td>Device :</td></tr><tr><td>Device Name</td><td>CO2 Standard (included in the CO2 Reagent kit from Roche)</td><td>ABX Pentra CO2 Cal</td></tr><tr><td>Method :</td><td>Calibration of Roche bicarbonate/CO2 measurement method</td><td>Calibration of HORIBA ABX bicarbonate/CO2 measurement method</td></tr><tr><td>Component matrices</td><td>Vial (liquid) Solution containing 30 mmol/l bicarbonate</td><td>Vial (liquid) Solution containing 30 mmol/1 bicarbonate</td></tr></table>

ABX Pentra $\underline { { \mathbf { C } \mathbf { O } _ { 2 } } }$ Control:   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Predicate device (K891475):</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">Lyphocheck AssayedChemistry Control Levels 1and 2</td><td colspan="1" rowspan="1">ABX Pentra CO2 Control</td></tr><tr><td colspan="1" rowspan="1">Manufactured by</td><td colspan="1" rowspan="1">Bio-Rad Laboratories</td><td colspan="1" rowspan="1">HORIBA ABX, France</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">ABX PENTRA 400</td></tr><tr><td colspan="1" rowspan="1">Method :</td><td colspan="1" rowspan="1">Multi-parameter control bymonitoring accuracy andprecision for the quantitativemethods as specified in theenclosed value sheet</td><td colspan="1" rowspan="1">Single-parameter control bymonitoring the performancesof Bicarbonate/Total CO2determination with ABXPentra CO2 RTU reagent</td></tr><tr><td colspan="1" rowspan="1">Component reagentmatrices</td><td colspan="1" rowspan="1">Vial (lyophilized)Human serum based withadded constituents of purifiedbiochemicals, pure chemicals,therapeutic drugs,preservatives and stabilizers</td><td colspan="1" rowspan="1">Vial (liquid)Aqueous matrix with addedCO2</td></tr><tr><td colspan="1" rowspan="1">Controlled molecules</td><td colspan="1" rowspan="1">The exact control values aregiven in the notice- Multiple parameters,including CO2</td><td colspan="1" rowspan="1">The exact control values aregiven in the enclosed annex- CO2</td></tr><tr><td colspan="1" rowspan="1">Performance data :Theoretical values andconfidence intervals</td><td colspan="1" rowspan="1">- The mean values are derivedfrom replicate analyses andare lot specific. The testslisted were performed by thereagent manufacturer and/orindependent laboratoriesusing manufacturer supportedreagents and a representativesampling of this lot of control.</td><td colspan="1" rowspan="1">- The assigned values aretraceable with a referencematerial in accordance withestablished protocols.- The assigned values andprecise confidence intervalare indicated in the annexenclosed in the kit</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Guidance for Industry and FDA Staff : “Format for Traditional & Abbreviated 510(k)s” : August 12, 2005

“In vitro diagnostics devices : Guidance for the preparation of 510(k) submissions” Jan 1997

“Guidance for Industry – In vitro diagnostics Bicarbonate/Carbon Dioxide Test System” July 1998

“Guidance for Industry – In vitro diagnostics Urea Nitrogen Test System” July 1998 “Guidance for Industry – In vitro diagnostics Creatinine Test System” July 1998 “Guidance for Industry and FDA Staff Bundling Multiple Devices or Multiple Indications in a Single Submission” November 2003

- CLSI (NCCLS) :

i) EP05-A2 – Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Second Edition   
ii) EP06-A - Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline   
iii) EP09-A2 – Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline -Second Edition   
iv) EP21-A - Estimation of Total Analytical Error for Clinical Laborator Methods; Approved Guideline

# L. Test Principle:

The ABX PENTRA ALP CP is a kinetic photometric test using pNitrophenylphosphate.

The ABX PENTRA Calcium CP is a photometric test using orthocresolphtalein complexone.

The ABX PENTRA $\mathbf { C O } _ { 2 }$ RTU is enzymatic test using phosphoenolpyruvate (PEP), phosphorenolpyruvate carboxylase (PEPC) and an analog of NADH.

The ABX PENTRA Creatinine CP is a kinetic method using alkaline picrate (Jaffé method).

The ABX PENTRA Iron CP is a photometric test based upon the Ferene method.

The ABX PENTRA Magnesium RTU is a photometric test using xylidyl blue.

The ABX PENTRA Phosphorus CP is UV method using phosphomolybdate.

The ABX PENTRA Urea CP is an enzymatic UV test using urease and glutamate dehydrogenase.

The ABX PENTRA Uric Acid CP is an enzymatic test of uric acid using a chromogenic system in the presence of peroxidase and uricase (Trinder method)

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility:

# ABX PENTRA ALP CP

Repeatability (Within run precision) - 2 controls and 3 specimens of low, medium and high concentrations were tested 20 times in a single run for each sample.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(U/L)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>90.79</td><td rowspan=1 colspan=1>1.27</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>252.68</td><td rowspan=1 colspan=1>0.62</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>28.05</td><td rowspan=1 colspan=1>3.98</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>54.88</td><td rowspan=1 colspan=1>2.42</td></tr><tr><td rowspan=1 colspan=1>Specimen 3</td><td rowspan=1 colspan=1>430.87</td><td rowspan=1 colspan=1>0.84</td></tr></table>

Reproducibility (Total precision) - Based upon CLSI EP-5A, two specimens of low & high levels and 2 controls were tested in duplicate for 20 days, two runs per day.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(U/L)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>90.79</td><td rowspan=1 colspan=1>3.62</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>254.38</td><td rowspan=1 colspan=1>2.39</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>64.11</td><td rowspan=1 colspan=1>4.36</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>190.44</td><td rowspan=1 colspan=1>2.66</td></tr></table>

# ABX PENTRA Calcium CP

Repeatability (Within run precision) - 2 controls and 3 specimens of low, medium and high concentrations were tested 20 times in a single run for each sample.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>0.92</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>15.22</td><td rowspan=1 colspan=1>0.42</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>6.56</td><td rowspan=1 colspan=1>0.81</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>9.32</td><td rowspan=1 colspan=1>0.51</td></tr><tr><td rowspan=1 colspan=1>Specimen 3</td><td rowspan=1 colspan=1>16.36</td><td rowspan=1 colspan=1>0.51</td></tr></table>

Reproducibility (Total precision) - Based upon CLSI EP-5A, two specimens of low & high levels and 2 controls were tested in duplicate for 20 days, two runs per day.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>9.34</td><td rowspan=1 colspan=1>1.58</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>15.20</td><td rowspan=1 colspan=1>1.57</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>7.04</td><td rowspan=1 colspan=1>1.49</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>15.83</td><td rowspan=1 colspan=1>1.67</td></tr></table>

# ABX PENTRA CO2 RTU

Repeatability (Within run precision) - 1 control and 3 specimens of low, medium and high concentrations were tested 20 times in a single run for each sample.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>20.44</td><td rowspan=1 colspan=1>1.25</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>10.93</td><td rowspan=1 colspan=1>0.78</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>21.30</td><td rowspan=1 colspan=1>0.51</td></tr><tr><td rowspan=1 colspan=1>Specimen 3</td><td rowspan=1 colspan=1>32.03</td><td rowspan=1 colspan=1>0.66</td></tr></table>

Reproducibility (Total precision) - Based upon CLSI EP-5A, two specimens of low & high levels and 1 control were tested in duplicate for 20 days, two runs per day.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>20.75</td><td rowspan=1 colspan=1>4.77</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>9.53</td><td rowspan=1 colspan=1>7.70</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>31.57</td><td rowspan=1 colspan=1>5.93</td></tr></table>

# ABX PENTRA Creatinine CP

Repeatability (Within run precision) - 2 controls and 3 specimens of low, medium and high concentrations were tested 20 times in a single run for each sample.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>1.28</td><td rowspan=1 colspan=1>1.58</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>3.38</td><td rowspan=1 colspan=1>0.66</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>2.09</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>0.71</td></tr><tr><td rowspan=1 colspan=1>Specimen 3</td><td rowspan=1 colspan=1>7.64</td><td rowspan=1 colspan=1>0.39</td></tr></table>

Reproducibility (Total precision) - Based upon CLSI EP-5A, two specimens of low & high levels and 2 controls were tested in duplicate for 20 days, two runs per day.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>1.27</td><td rowspan=1 colspan=1>3.47</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>3.45</td><td rowspan=1 colspan=1>2.56</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>1.29</td><td rowspan=1 colspan=1>3.69</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>6.75</td><td rowspan=1 colspan=1>2.04</td></tr></table>

# ABX PENTRA Iron CP

Repeatability (Within run precision) - 2 controls and 3 specimens of low, medium and high concentrations were tested 20 times in a single run for each sample.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(ug/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>115.36</td><td rowspan=1 colspan=1>1.89</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>189.92</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>50.41</td><td rowspan=1 colspan=1>2.56</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>95.91</td><td rowspan=1 colspan=1>2.32</td></tr><tr><td rowspan=1 colspan=1>Specimen 3</td><td rowspan=1 colspan=1>680.26</td><td rowspan=1 colspan=1>0.32</td></tr></table>

Reproducibility (Total precision) - Based upon CLSI EP-5A, two specimens of low & high levels and 2 controls were tested in duplicate for 20 days, two runs per day.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(ug/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>116.83</td><td rowspan=1 colspan=1>2.98</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>191.05</td><td rowspan=1 colspan=1>2.61</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>74.4</td><td rowspan=1 colspan=1>3.61</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>510.99</td><td rowspan=1 colspan=1>1.78</td></tr></table>

# ABX PENTRA Magnesium RTU

Repeatability (Within run precision) - 2 controls and 3 specimens of low, medium and high concentrations were tested 20 times in a single run for each sample.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>2.44</td><td rowspan=1 colspan=1>2.02</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>4.19</td><td rowspan=1 colspan=1>1.28</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>1.58</td><td rowspan=1 colspan=1>2.28</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>2.27</td><td rowspan=1 colspan=1>1.92</td></tr><tr><td rowspan=1 colspan=1>Specimen 3</td><td rowspan=1 colspan=1>2.86</td><td rowspan=1 colspan=1>1.98</td></tr></table>

Reproducibility (Total precision) - Based upon CLSI EP-5A, two specimens of low & high levels and 2 controls were tested in duplicate for 20 days, two runs per day.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>2.50</td><td rowspan=1 colspan=1>3.19</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>4.27</td><td rowspan=1 colspan=1>2.80</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>2.20</td><td rowspan=1 colspan=1>2.63</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>3.19</td><td rowspan=1 colspan=1>2.79</td></tr></table>

# ABX PENTRA Phosphorus CP

Repeatability (Within run precision) - 2 controls and 3 specimens of low, medium and high concentrations were tested 20 times in a single run for each sample.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>4.08</td><td rowspan=1 colspan=1>1.26</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>6.34</td><td rowspan=1 colspan=1>0.77</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>2.39</td><td rowspan=1 colspan=1>2.48</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>3.48</td><td rowspan=1 colspan=1>1.61</td></tr><tr><td rowspan=1 colspan=1>Specimen 3</td><td rowspan=1 colspan=1>9.19</td><td rowspan=1 colspan=1>1.38</td></tr></table>

Reproducibility (Total precision) - Based upon CLSI EP-5A, two specimens of low & high levels and 2 controls were tested in duplicate for 20 days, two runs per day.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>4.01</td><td rowspan=1 colspan=1>2.50</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>6.35</td><td rowspan=1 colspan=1>1.82</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>2.50</td><td rowspan=1 colspan=1>3.56</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>11.44</td><td rowspan=1 colspan=1>1.38</td></tr></table>

# ABX PENTRA Urea CP

Repeatability (Within run precision) - 2 controls and 3 specimens of low, medium and high concentrations were tested 20 times in a single run for each sample.

Urea Nitrogen:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>40.1</td><td rowspan=1 colspan=1>2.27</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>155.6</td><td rowspan=1 colspan=1>1.66</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>12.9</td><td rowspan=1 colspan=1>2.76</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>44.6</td><td rowspan=1 colspan=1>1.58</td></tr><tr><td rowspan=1 colspan=1>Specimen 3</td><td rowspan=1 colspan=1>182.7</td><td rowspan=1 colspan=1>1.80</td></tr></table>

Blood Urea Nitrogen:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>18.73</td><td rowspan=1 colspan=1>2.27</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>72.78</td><td rowspan=1 colspan=1>1.66</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>6.02</td><td rowspan=1 colspan=1>2.76</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>20.86</td><td rowspan=1 colspan=1>1.58</td></tr><tr><td rowspan=1 colspan=1>Specimen 3</td><td rowspan=1 colspan=1>85.46</td><td rowspan=1 colspan=1>1.80</td></tr></table>

Reproducibility (Total precision) - Based upon CLSI EP-5A, two specimens of low & high levels and 2 controls were tested in duplicate for 20 days, two runs per day.

Urea Nitrogen:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>39.4</td><td rowspan=1 colspan=1>2.14</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>153.2</td><td rowspan=1 colspan=1>1.93</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>149.9</td><td rowspan=1 colspan=1>2.14</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>70.12</td><td rowspan=1 colspan=1>1.97</td></tr></table>

Blood Urea Nitrogen:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>18.45</td><td rowspan=1 colspan=1>2.14</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>71.69</td><td rowspan=1 colspan=1>1.93</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>19.24</td><td rowspan=1 colspan=1>2.14</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>70.12</td><td rowspan=1 colspan=1>1.97</td></tr></table>

# ABX PENTRA Uric Acid CP

Repeatability (Within run precision) - 2 controls and 3 specimens of low, medium and high concentrations were tested 20 times in a single run for each sample.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>4.62</td><td rowspan=1 colspan=1>0.45</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>11.63</td><td rowspan=1 colspan=1>0.34</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>2.53</td><td rowspan=1 colspan=1>1.24</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>4.58</td><td rowspan=1 colspan=1>0.91</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>7.19</td><td rowspan=1 colspan=1>1.02</td></tr></table>

Reproducibility (Total precision) - Based upon CLSI EP-5A, two specimens of low & high levels and 2 controls were tested in duplicate for 20 days, two runs per day.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean Value(Mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal Control</td><td rowspan=1 colspan=1>4.64</td><td rowspan=1 colspan=1>2.81</td></tr><tr><td rowspan=1 colspan=1>Abnormal Control</td><td rowspan=1 colspan=1>11.73</td><td rowspan=1 colspan=1>1.39</td></tr><tr><td rowspan=1 colspan=1>Specimen 1</td><td rowspan=1 colspan=1>4.67</td><td rowspan=1 colspan=1>2.64</td></tr><tr><td rowspan=1 colspan=1>Specimen 2</td><td rowspan=1 colspan=1>6.74</td><td rowspan=1 colspan=1>2.51</td></tr></table>

$b$ . Linearity/assay reportable range: Linearity studies across the measuring range of the assay were performed via protocols based upon CLSI EP6-A. The studies demonstrated linearity of the

assays and the linear regression statistics listed below. In addition, post dilution studies were performed to validated the automated dilution function and range.

# ABX PENTRA ALP CP

The measuring range of the assay is $6 - 1 5 0 0 \mathrm { U / L }$ ; Post dilution up to $6 0 0 0 \mathrm { U } / \mathrm { L }$

Linear regression statistics: $\mathbf { y } = 0 . 9 4 6 1 \mathbf { x } + 1 5 . 8 9 ; \mathbf { R } ^ { 2 } = 0 . 9 9 9 3$

# ABX PENTRA Calcium CP

The measuring range of the assay is $0 . 1 6 - 2 0 \mathrm { m g / d L }$ ; Post dilution up to 40 mg/dL.

Linear regression statistics: $\mathbf { y } = 1 . 0 4 5 1 \mathrm { x } - 0 . 1 2 2 1 ; \mathrm { R } ^ { 2 } = 0 . 9 9 9 4$

# ABX PENTRA CO2 RTU

The measuring range of the assay is $1 . 8 - 6 0 . 8 \mathrm { m m o l / L }$ ; Post dilution up to 121 mmol/L.

Linear regression statistics: $\mathbf { y } = 1 . 0 2 0 1 \mathbf { x } - 0 . 2 9 6 7 ; \mathbf { R } ^ { 2 } = 0 . 9 9 9 9$

# ABX PENTRA Creatinine CP

The measuring range of the assay is $0 . 1 1 - 1 5 . 8 \mathrm { m g / d L }$ ; Post dilution up to 79 $\mathrm { m g / d L }$ .

Linear regression statistics: $\mathbf { y } = 0 . 9 4 4 8 \mathbf { x } + 2 0 . 0 5 ; \mathbf { R } ^ { 2 } = 0 . 9 9 9 7$

# ABX PENTRA Iron CP

The measuring range of the assay is $7 . 4 2 - 1 0 0 4 \ : \mu \mathrm { g / d L }$ ; Post dilution up to 5020 $\mu \mathrm { g / d L }$ .

Linear regression statistics: $\mathbf { y } = 1 . 0 0 6 5 \mathrm { x } - 0 . 3 5 0 2 ; \mathrm { R } ^ { 2 } > 0 . 9 9 9 9$

# ABX PENTRA Magnesium RTU

The measuring range of the assay is $0 . 1 7 - 4 . 6 4 \ : \mathrm { m g / d L }$ ; Post dilution up to 13.92 $\mathrm { m g / d L }$ .

Linear regression statistics: $\mathrm { y } = 0 . 9 2 7 7 \mathrm { x } + 0 . 0 5 1 5 ; \mathrm { R } ^ { 2 } = 0 . 9 9 8$

# ABX PENTRA Phosphorus CP

The measuring range of the assay is $0 . 2 8 - 2 4 . 1 8 \mathrm { m g / d L }$ ; Post dilution up to 96.72 mg/dL.

Linear regression statistics: $\mathbf { y } = 1 . 0 1 4 6 \mathbf { x } - 0 . 0 4 3 ; \mathbf { R } ^ { 2 } = 0 . 9 9 9 8$

# ABX PENTRA Urea CP

The measuring range of the assay is $0 . 9 \textrm { -- } 3 0 0 \mathrm { m g } / \mathrm { d L } ( 0 . 9 - 1 4 0 . 3 \mathrm { m g } / \mathrm { d L }$ for BUN);   
Post dilution up to $1 5 0 0 \mathrm { m g / d L }$ (up to 701.5 for BUN).

Linear regression statistics: $\mathrm { y } = 0 . 9 8 7 8 \mathrm { x } + 0 . 1 5 8 3 ; \mathrm { R } ^ { 2 } = 0 . 9 9 9 8$

# ABX PENTRA Uric Acid CP

The measuring range of the assay is $0 . 1 9 - 2 5 \mathrm { m g / d L }$ ; Post dilution up to 75 $\mathrm { m g / d L }$ .

Linear regression statistics: $\mathrm { y } = 1 . 0 1 7 3 \mathrm { x } - 1 . 2 2 0 4 ; \mathrm { R } ^ { 2 } > . 9 9 9 9$

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Protocols and acceptance criteria for on-board and shelf life stability studies were described and found to be acceptable.

# ABX Pentra $\mathbf { C O } _ { 2 }$ Control traceability

The ABX Pentra $\mathrm { C O } _ { 2 }$ Control is gravimetrically prepared to a concentration of $2 0 \mathrm { m m o l } / 1$ sodium bicarbonate. The value of the ABX Pentra $\mathrm { C O } _ { 2 }$ Control is assigned using a biochemistry analyzer, e.g. Hitachi 911.

# ABX Pentra $\mathbf { C O } _ { 2 }$ Calibrator traceability

ABX Pentra $\mathrm { C O } _ { 2 }$ Cal is made from a secondary reference material, traceable to NIST 723c to a concentration of $3 0 \mathrm { m m o l } / 1$ sodium bicarbonate. The Master Lot is stored under the same conditions as a normal production lot, and has the same expiration date: 15 months after production at $2 { - } 8 ^ { \circ } \mathrm { C }$ . The target value is determined by the median of all results yielded from the 6 devices (150 measurements/parameter).

# d. Detection limit:

Method: Based upon the Valtec guideline (Vassault et al., Ann. Biol. Clin., 1986, (44), 686-745)

Minimum Detection Limit (MDL) was calculated from 30 measurements of saline water $( 0 . 9 \ : \mathrm { g } / 1 )$

Formula : $\mathrm { { M D L } = }$ mean of measurements $+ 4 . 6 5$ SD (mean of measurement $=$ 0 when negative

Using the above criteria, the following minimum detection limits were determined:

# ABX PENTRA ALP CP - 6 U/L

ABX PENTRA Calcium CP - 0.16 Mg/dL ABX PENTRA CO2 RTU - 1.8 mmol/L ABX PENTRA Creatinine CP - 0.11 Mg/dL ABX PENTRA Iron CP - 7.42 ųg/dL ABX PENTRA Magnesium RTU - 0.17 Mg/dL ABX PENTRA Phosphorus $\mathbf { C P } - 0 . 2 8 ~ \mathrm { M g / d L }$ ABX PENTRA Urea CP - 0.9 Mg/dL ABX PENTRA Uric Acid CP - 0.19 Mg/dL

# e. Analytical specificity:

Substances were added to pooled Human serum samples at two different measurand concentrations (normal and high). The base serum with each interfering substance was then serially diluted with the same base serum containing saline instead of interfering substance to adjust for analyte concentration.

Method: Based upon the Valtec guideline (Vassault et al., Ann. Biol. Clin., 1986, (44), 686-745)

ABX PENTRA ALP CP - Hemoglobin up to $1 9 5 \mathrm { \ : \mu m o l / l }$ $3 . 3 6 \mathrm { g } / 1$ or 336 $\mathrm { m g / d l } )$ , total bilirubin up to $4 7 0 \ \mathrm { \mu m o l / l }$ $( 2 7 . 5 \mathrm { m g / d l } )$ , direct bilirubin up to 250 $\mu \mathrm { m o l } / 1$ ( $1 4 . 6 \mathrm { m g / d l } )$ and triglycerides (as Intralipid $^ \mathrm { \textregistered }$ , representative of lipemia) up to 7 mmol/l $\mathrm { 6 1 2 . 5 \ m g / d l ) }$ do not interfere with ALP determination by this test.

ABX PENTRA Calcium CP - Hemoglobin up to $1 9 5 \ \mathrm { \textmu m o l / l } \ ( 3 . 3 6 \ \mathrm { g / l }$ or 336 $\mathrm { m g / d l } )$ , Total Bilirubin up to $1 0 1 ~ \mu \mathrm { m o l } / 1$ $\mathrm { \xi . 9 1 \ m g / d l ) }$ , direct bilirubin up to $1 3 5 7 \mathrm { \mu m o l / l }$ ( $7 9 . 4 \ : \mathrm { m g / d l } )$ ) and triglycerides (as Intralipid $^ \mathrm { \textregistered }$ , representative of lipemia) up to $7 \mathrm { m m o l } / 1$ $6 1 2 . 5 \mathrm { m g / d l } )$ do not interfere with calcium determination by this test.

ABX PENTRA CO2 RTU - Hemoglobin up to $1 9 5 \mathrm { \ : \mu m o l / l }$ ( $3 3 6 \mathrm { m g / d l } )$ , total bilirubin up to $2 5 0 \mu \mathrm { m o l } / 1$ ( $1 4 . 6 \mathrm { m g / d l } )$ , direct bilirubin up to $3 7 0 \ \mathrm { \textmu m o l / l }$ (21.6 $\mathrm { m g / d l } )$ and triglycerides (as Intralipid $^ \mathrm { \textregistered }$ , representative of lipemia) up to 7 mmol/l ( $6 1 2 . 5 \mathrm { m g / d l } )$ do not interfere with bicarbonates determination by this test.

ABX PENTRA Creatinine CP - Hemoglobin up to $3 1 9 \mathrm { \ : \mu m o l / l }$ ( $5 5 0 \mathrm { m g / d l } )$ , total bilirubin up to $1 7 6 \mathrm { \ : \mu m o l / l }$ ( $1 0 . 3 0 \mathrm { m g / d l } )$ , direct bilirubin up to $9 2 \mathrm { \ : \mu m o l / l }$ $( 5 . 3 8 \mathrm { m g } / \mathrm { d l } )$ , triglycerides (as Intralipid $^ \mathrm { \textregistered }$ , representative of lipemia) up to 7 mmol/l ( $6 1 2 . 5 \mathrm { m g / d l } )$ and glucose up to 22.5 mmol/l $\mathrm { 4 0 5 \ m g / d l } )$ do not interfere with creatinine determination by this test.

ABX PENTRA Iron CP - Hemoglobin up to $1 0 4 \mathrm { \ : \mu m o l / l }$ ( $1 8 0 \mathrm { m g / d l } )$ , total bilirubin up to $3 2 1 ~ \mathrm { \mu m o l / l }$ ( $1 8 . 7 8 \mathrm { m g / d l } )$ , direct bilirubin up to $2 8 9 \mathrm { \ : \mu m o l / l }$ $( 1 6 . 9 1 \mathrm { m g / d l } )$ and triglycerides (as Intralipid $^ \mathrm { \textregistered }$ , representative of lipemia) up to $7 \mathrm { m m o l } / 1$ $6 1 2 . 5 \mathrm { m g / d l } )$ do not interfere with Iron determination by this test.

ABX PENTRA Magnesium RTU - Hemoglobin up to $1 9 5 \mathrm { \ : \mu m o l / l }$ (336 $\mathrm { m g / d l } )$ , total bilirubin up to $2 9 0 \ \mathrm { \mu m o l / l }$ ( $1 6 . 9 7 \mathrm { m g / d l } )$ , direct bilirubin up to $5 2 0 \ \mathrm { \textmu m o l / l }$ ( $3 0 . 4 2 \mathrm { m g / d l } )$ and triglycerides (as Intralipid $^ \mathrm { \textregistered }$ , representative of lipemia) up to $7 \mathrm { m m o l } / 1$ ( $6 1 2 . 5 \mathrm { m g / d l } )$ ) do not interfere with Magnesium determination by this test.

ABX PENTRA Phosphorus CP - Hemoglobin up to $7 2 . 5 \ \mathrm { \textmu m o l / l } \ ( 1 . 2 5 \ \mathrm { g / l }$ or $1 2 5 \mathrm { m g / d l } )$ , total bilirubin up to $1 0 2 . 6 \ \mu \mathrm { m o l } / 1$ $( 6 \mathrm { m g / d l } )$ , direct bilirubin up to $4 2 7 \mathrm { \mu m o l / l }$ $( 2 5 \mathrm { m g / d l } )$ and triglycerides (as Intralipid $^ \mathrm { \textregistered }$ , representative of lipemia) up to $3 \mathrm { m m o l } / 1$ $( 2 6 2 . 5 \mathrm { m g / d l } )$ do not interfere with Phosphorus determination by this test.

ABX PENTRA Urea CP - Hemoglobin up to $2 6 7 \ \mathrm { \mu m o l / l }$ $\mathrm { 4 6 0 \ m g / d l ) }$ , total bilirubin up to $3 8 0 \ \mathrm { \textmu m o l / l }$ $2 2 . 2 3 \mathrm { m g / d l } )$ , direct bilirubin up to $4 0 0 \ : \mu \mathrm { m o l / l }$ $( 2 3 . 4 0 \mathrm { m g / d l } )$ and triglycerides (as Intralipid $^ \mathrm { \textregistered }$ , representative of lipemia) up to $7 \mathrm { m m o l } / 1$ ( $6 1 2 . 5 \mathrm { m g / d l } )$ do not interfere with Urea/BUN determination by this test.

ABX PENTRA Uric Acid CP - Hemoglobin up to $2 9 0 \mu \mathrm { m o l } / 1$ $( 5 0 0 \mathrm { m g / d l } )$ , total bilirubin up to $6 1 6 \ : \mu \mathrm { m o l } / 1$ $( 3 6 \mathrm { m g / d l } )$ , direct bilirubin up to $5 1 3 ~ { \mu \mathrm { m o l } }$ (30 $\mathrm { m g / d l } )$ and triglycerides (as Intralipid $^ \mathrm { \textregistered }$ , representative of lipemia) up to 7 mmol/l ( $6 1 2 . 5 \mathrm { m g / d l } )$ do not interfere with uric acid determination by this test.

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device:

# ABX PENTRA ALP CP

A total of 105 samples were compared with the Roche Alkaline Phosphatase reagent (predicate) on the Roche MIRA Plus.

$$
\mathbf { y } = 1 . 0 6 9 2 \mathbf { x } - 5 . 1 2 5 9 , \mathrm { r } ^ { 2 } = 0 . 9 9 8 1
$$

Additional studies were performed to provide complementary data covering the Alkaline Phosphatase assay range $6 - 1 5 0 0 \mathrm { U / L }$ . Samples were spiked or diluted depending upon test conditions (high or low range study). Low range study: sample range $7 . 2 - 3 5 . 5 \mathrm { U } / \mathrm { L }$ , $\mathrm { n } { = } 1 4$ , $\mathrm { y } { = } 0 . 8 7 8 9 \mathrm { x } { - } 1 . 6 9 2 8$ , $\mathrm { r } ^ { 2 } { = } 0 . 9 8 3 3$ . High Range study: sample range 1247.8 – 1598U/L, $\mathrm { n } { = } 1 2$ , $\mathrm { y } { = } 1 . 0 6 3 4 \mathrm { x } { + } 4 3 . 3$ , $\mathrm { r } ^ { 2 } { = } 0 . 9 3 2$ .

# ABX PENTRA Calcium CP

A total of 95 samples were compared with the Roche Calcium reagent (predicate) on the Roche MIRA Plus.

$$
\mathrm { y } = 1 . 1 2 8 \mathrm { x } - 0 . 2 1 4 5 , \mathrm { r } ^ { 2 } = 0 . 9 5 0 1
$$

Additional studies were performed to provide complementary data covering the Calcium assay range $0 . 6 - 2 0 . 1 0 \mathrm { m g / d l }$ . Samples were spiked or diluted depending upon test conditions (high or low range study). Low range study: sample range $0 . 2 4 - 1 1 . 1 9 \mathrm { m g / d l }$ , $\mathrm { n } { = } 1 5$ , $\mathrm { y } { = } 1 . 0 4 0 9 \mathrm { x } + 0 . 1 0 3 4$ , $\mathrm { r } ^ { 2 } { = } 0 . { \overset { \vartriangle } { 9 } } 9 8 2$ . High Range study: sample range $1 6 . 8 - 2 2 . 4 6 \mathrm { { m g } / \mathrm { { d l } } }$ , $\mathrm { n } { = } 1 5$ , $\mathrm { y } { = } 1 . 2 5 0 7 \mathrm { x } - 1 . 9 0 1 2 .$ , $\mathrm { r } ^ { 2 } { = } 0 . \mathsf { 9 6 } 2 6$

# ABX PENTRA $\mathbf { C O } _ { 2 }$ RTU

A total of 97 samples were compared with the Roche $\mathrm { C O } _ { 2 }$ reagent on the Roche MIRA Plus.

$$
\mathbf { y } = 0 . 9 2 7 \mathbf { x } - 1 . 6 1 5 , \mathbf { r } ^ { 2 } = 0 . 9 7 6 3
$$

Additional studies were performed to provide complementary data covering the $\mathrm { C O } _ { 2 }$ RTU assay range $1 . 8 - 6 0 . 8 \mathrm { m m o l } / 1$ . Samples were spiked or diluted depending upon test conditions (high or low range study). Low range study: sample range $1 . 2 - 1 4 . 8 \ : \mathrm { m m o l } / 1$ , $\mathrm { n } { = } 1 5$ , $\mathrm { y } { = } 0 . 9 9 8 6 \mathrm { x } + 0 . 2 3 2 9$ , $\mathrm { r } ^ { 2 } { = } 0 . 9 \dot { 9 } 3 6$ . High Range study: sample range $2 3 . 2 - 4 1 . 9 \mathrm { m m o l } / 1$ , $\mathrm { n } { = } 1 4$ , $\mathrm { y } { = } 1 . 0 7 8 4 \mathrm { x } - 2 . 7 3 6 9$ , $\mathrm { r } ^ { 2 } { = } 0 . \overset { \sim } { 9 } 2 1 7$

# ABX PENTRA Creatinine CP

A total of 95 samples were compared with the Roche Creatinine reagent on the Roche MIRA Plus.

$$
\mathbf { y } = 1 . 0 1 0 9 \mathbf { x } - 1 8 . 7 3 5 , \mathbf { r } ^ { 2 } = 0 . 9 9 5 5
$$

Additional studies were performed to provide complementary data covering the Creatinine assay range $0 . 1 1 - 1 5 . 8 \mathrm { m g / d l }$ . Samples were spiked or diluted depending upon test conditions (high or low range study). Low range study: sample range $0 . 0 8 - 1 . 0 2 \mathrm { m g / d l }$ , $\mathrm { n } { = } 1 6$ , $\mathrm { y } { = } 1 . 0 4 1 7 \mathrm { x } + 0 . 0 7 7 9$ , $\mathrm { r } ^ { 2 } { = } 0 . 9 \overline { { 4 3 } } 8$ . High Range study: sample range $8 . 8 2 - 1 6 . 3 5 \mathrm { m g / d l }$ , $\mathrm { n } { = } 1 3$ , $\mathrm { y } { = } 1 . 0 2 4 1 \mathrm { x } - 0 . 7 8 0 7$ , $\mathrm { r } ^ { 2 } { = } 0 . \mathsf { 9 } 7 5 9$

# ABX PENTRA Iron CP

A total of 98 samples were compared with the Raichem Iron reagent on the Roche MIRA Plus.

$$
\mathbf { y } = 1 . 1 3 0 7 \mathbf { x } + 0 . 8 8 , \mathbf { r } ^ { 2 } = 0 . 9 9 7 5
$$

Additional studies were performed to provide complementary data covering the Creatinine assay range $0 . 1 1 - 1 5 . 8 \mathrm { m g / d l }$ . Samples were spiked or diluted depending upon test conditions (high or low range study). Low range study: sample range $0 . 0 8 - 1 . 0 2 \mathrm { m g / d l }$ , $\mathrm { n } { = } 1 6$ , $\mathrm { y } { = } 1 . 0 4 1 7 \mathrm { x } + 0 . 0 7 7 9$ , $\mathrm { r } ^ { 2 } { = } 0 . 9 \overline { { 4 3 } } 8$ . High Range study: sample range $8 . 8 2 - 1 6 . 3 5 \mathrm { m g / d l } .$ , $\mathrm { n } { = } 1 3$ , $\mathrm { y } { = } 1 . 0 2 4 1 \mathrm { x } - 0 . 7 8 0 7$ , $\mathrm { r } ^ { 2 } { = } 0 . \mathrm { 9 } 7 5 9$

# ABX PENTRA Magnesium RTU

A total of 75 samples were compared with the Roche Magnesium reagent on the Roche MIRA Plus.

$$
\mathrm { y } = 1 . 2 5 3 2 \mathrm { x } - 0 . 1 0 1 8 , \mathrm { r } ^ { 2 } = 0 . 9 7 1 2
$$

Additional studies were performed to provide complementary data covering the Magnesium assay range $0 . 1 7 - 4 . 6 4 \mathrm { m g / d l }$ . Samples were spiked or diluted depending upon test conditions (high or low range study). Low range study: sample range $0 . 1 9 - 1 . 3 8 \mathrm { m g / d l }$ , $\mathrm { n } { = } 1 8$ , $\mathrm { y } { = } 1 . 1 6 4 4 \mathrm { x } - 0 . 2 4 2 8 .$ , $\mathrm { r } ^ { 2 } { = } 0 . 8 6 \overline { { 7 } } 4$ High Range study: sample range $0 . 1 9 - 6 . 4 2 \mathrm { m g / d l } .$ , $\mathtt { n } { = } 9 3$ , $\mathrm { y } { = } 1 . 2 7 0 7 \mathrm { x } -$ 0.3034, $\mathrm { r } ^ { 2 } { = } 0 . 9 8 4 { \dot { 9 } }$ .

# ABX PENTRA Phosphorus CP

A total of 105 samples were compared with the Roche Phosphorus reagent on the Roche MIRA Plus.

$$
\mathrm { y } = 1 . 0 3 5 \mathrm { x } + 0 . 0 8 5 8 , \mathrm { r } ^ { 2 } = 0 . 9 9 6 7
$$

Additional studies were performed to provide complementary data covering the Phosphorus assay range $0 . 2 8 - 2 4 . 1 8 \mathrm { m g } / \mathrm { d l }$ . Samples were spiked or diluted depending upon test conditions (high or low range study). Low range study: sample range $0 . 2 5 - 2 . 2 3 ~ \mathrm { m g / d l }$ , $\mathrm { n } { = } 1 4$ , $\mathrm { y } { = } 1 . 1 0 7 5 \mathrm { x } - 0 . 0 0 2 9$ , $\mathrm { r } ^ { 2 } { = } 0 . 9 8 \overline { { 9 } } 6$ . High Range study: sample range $1 5 . 1 6 - 2 5 . 0 5 \mathrm { m g / d l }$ , $\mathrm { n } { = } 1 3$ , $\mathrm { y } { = } 1 . 2 1 5 6 \mathrm { x } -$ 2.9012, $\mathrm { r } ^ { 2 } { = } 0 . 9 7 8$

# ABX PENTRA Urea CP

A total of 108 samples were compared with the Roche BUN reagent on the Roche MIRA Plus.

Urea (mmol/L) $\mathrm { y } = 1 . 0 3 9 \mathrm { x } + 0 . 1 1 6 , \mathrm { r } ^ { 2 } = 0 . 9 9 0 4$

BUN $\mathrm { ( m g / d L ) }$ $\mathrm { y } { = } 1 . 0 3 9 \mathrm { x } { + } 0 . 6 9 7 , \mathrm { r } ^ { 2 } { = } 0 . 9 9 0 5$

Additional studies were performed to provide complementary data covering the BUN assay range $0 . 9 - 1 4 0 . 3 \mathrm { m g / d l }$ . Samples were tested based upon recommendations in NCCLS (CLSI) EP-9A2 guidance. Samples were spiked or diluted depending upon test conditions (high or low range study). Low range study: sample range $0 . 7 9 - 5 . 2 5 \mathrm { m g / d l }$ , $\mathrm { n } { = } 1 5$ , $\mathrm { y } { = } 0 . 8 3 3 4 \mathrm { x } + 0 . 1 9 0 3$ , $\mathrm { r } ^ { 2 } { = } \breve { 0 } . 9 4 8 4$ . High Range study: sample range $9 5 . 7 9 - 1 3 8 . 8 9 \mathrm { m g / d l }$ , $\mathrm { n } { = } 1 3$ , $\mathrm { y } { = } 0 . 8 8 6 2 \mathrm { x } + 1 4 . 6 7 7$ , $\stackrel { - } { \mathrm { r } } ^ { 2 } = 0 . 9 \dot { 9 } 3$ .

# ABX PENTRA Uric CP

A total of 98 samples were compared with the Roche Uric Acid reagent on the Roche MIRA Plus.

$$
\mathrm { y } { = } 0 . 0 9 3 6 \mathrm { x } { + } 1 4 . 1 4 . 1 3 , \mathrm { r } ^ { 2 } { = } 0 . 9 5 7 9
$$

Additional studies were performed to provide complementary data covering the Uric Acid assay range $0 . 1 9 - 2 5 \mathrm { m g / d l }$ . Samples were spiked or diluted depending upon test conditions (high or low range study). Low range study: sample range $0 . 1 5 - 2 . 4 2 \mathrm { m g / d l }$ , $\mathrm { n } { = } 1 5$ , $\mathrm { y } { = } 0 . 8 9 9 \mathrm { x } - 0 . 0 0 1$ , $\mathrm { r } ^ { 2 } { = } 0 . 9 9 2 { \overline { { 7 } } }$ . High Range study: sample range $7 . 7 4 - 2 3 . 9 6 \mathrm { m g / d l }$ , $\mathrm { n } { = } 1 9$ , $\mathrm { y } { = } 0 . 9 4 2 \mathrm { x } - 0 . 1 2 2$ , $\mathrm { r } ^ { 2 } { = } 0 . \mathsf { 9 9 3 } 6$ .

# b. Matrix comparison:

Method : To demonstrate equivalence of analyte results in serum and Plasma Heparin-Lithium samples, comparison study was performed on samples that were evaluated on Pentra 400 analyzer using ABX Pentra reagents. Comparisons were made serum vs plasma for corresponding samples.

# ABX PENTRA ALP CP

Slope: $\mathrm { y } = 0 . 9 4 8 6 \mathrm { x } + 0 . 2 4 8 8$ , $\mathrm { r } ^ { 2 } = 0 . 9 9 2$ , $\mathrm { N } = 4 5$ on serum versus LithiumHeparin Plasma

# ABX PENTRA Calcium CP

Slope: $\mathrm { y } = 0 . 6 9 0 3 \mathrm { x } + 0 . 7 8 2 2$ , $\mathrm { r } ^ { 2 } = 0 . 6 4 9$ , $\mathrm { N } = 4 3$ on serum versus LithiumHeparin Plasma

Because of 3 outliers at the higher end of the range, the sponsor also performed Passing-Bablock analysis:

Variable X : Serum Variable Y : Plasma

In mmol/l: $\mathrm { y } = \mathrm { 0 . 9 7 1 4 x + 0 . 0 9 4 3 }$

Intercept $9 5 \%$ CI: -0.2190 to 0.4271   
Slope $9 5 \%$ CI: 0.8387 to 1.1000

# ABX PENTRA $\mathbf { C O } _ { 2 }$ RTU

Slope: $\mathrm { y } = 0 . 9 2 0 0 \mathrm { x } - 0 . 1 7 0 0$ , $\mathrm { r } ^ { 2 } = 0 . 7 5 6 9$ , $_ { \mathrm { N } = 3 3 }$ on serum versus LithiumHeparin Plasma

# ABX PENTRA Creatinine CP

Slope: $\mathrm { y } = 1 . 0 2 2 7 \mathrm { x } { - 4 . 1 0 7 2 } , \mathrm { N } { = }$ $\Nu { = } 3 4$ on serum versus Lithium-Heparin Plasma

ABX PENTRA Iron CP

Slope: $\mathrm { y } = 0 . 9 8 8 5 \mathrm { x } + 0 . 3 4 8$ , $\mathrm { r } ^ { 2 } = 0 . 7 5 6 9$ , $\mathrm { N } { = } 4 0$ on serum versus LithiumHeparin Plasma

# ABX PENTRA Magnesium RTU

Slope: $\mathrm { y } = 0 . 9 7 1 \mathrm { x } - 0 . 0 1 8 5$ , $\mathrm { r } ^ { 2 } = 0 . 9 8 8 3$ , $_ { \mathrm { N } = 4 1 }$ on serum versus LithiumHeparin Plasma

# ABX PENTRA Phosphorus CP

Slope: $\mathrm { y } = 0 . 9 8 5 8 \mathrm { x } + 0 . 0 2 5 5$ , $\mathrm { r } ^ { 2 } = 0 . 9 9 8 1$ , $_ { \mathrm { N } = 4 2 }$ on serum versus LithiumHeparin Plasma

# ABX PENTRA Urea CP

Urea (mmol/L)

Slope: $\mathrm { y } = 0 . 9 9 8 6 \mathrm { x } + 0 . 0 2 1 1$ , $\mathrm { r } ^ { 2 } = 0 . 9 9 4$ , $\Nu { = } 4 3$ on serum versus LithiumHeparin Plasma

BUN $\mathrm { ( m g / d L ) }$

Slope: $\mathrm { y } = 0 . 9 9 8 6 \mathrm { x } + 0 . 0 5 9 3$ , $\mathrm { r } ^ { 2 } = 0 . 9 9 4$ , $\Nu { = } 4 3$ on serum versus LithiumHeparin Plasma

# ABX PENTRA Uric Acid CP

Slope $\mathrm { y } { = } 1 . 0 2 2 4 \mathrm { x } { - } 2 . 3 0 3 5 \mathrm { r } ^ { 2 } { = } 0 . 9 9 5 2 , \mathrm { N } { = } 3 6$ on serum versus Lithium-Heparin Plasma

The results support equivalency of serum specimens and Heparin-Lithium Plasma for the above assays.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable   
b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

# ABX PENTRA ALP CP

Adults $( 3 7 ^ { \circ } \mathrm { C } ) : ( 1 )$ Women 20 - 50 [U/l] 42 - 98 years Men 20 - 50 years [U/l] 53 - 128 Women $> 6 0$ years [U/l] 53 - 141 Men $> 6 0$ years [U/l] 56 - 119

Children $( 3 7 ^ { \circ } \mathbf { C } ) : ( 2 )$ Female Male   
1 - 30 days [U/l] 48 - 406 75 - 319   
1 month - 1 year [U/l] 124 - 341 82 - 383   
1 - 3 year(s) [U/l] 108 - 317 104 - 345   
4 - 6 years [U/l] 96 - 297 93 - 309   
7 - 9 years [U/l] 69 - 325 86 - 315   
10 - 12 years [U/l] 51 - 332 42 - 362   
13 - 15 years [U/l] 50 - 162 74 - 390   
16 - 18 years [U/l] 47 - 119 52 - 171

# References:

1. Burtis CA, Ashwood ER. Eds. Tietz textbook of clinical chemistry. $3 ^ { \mathrm { r d } }$ ed.   
Philadelphia: W. B. Saunders Company, 1999. p. 1829.

2. Soldin JS, Hicks JM. Pediatric reference ranges. Washington: AACC Press, 1996. p. 5.

# ABX PENTRA Calcium CP

Serum / Plasma: $8 . 6 - 1 0 . 3 \ \mathrm { m g / d l }$ (2.15 - 2.57 mmol/l)

Reference:

Endres D.B., Rude R.K. Mineral and bone metabolism. In: Burtis C.A., Ashwood E.R., editors. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: W.B. Saunders Company; 1999. p. 1395-1457.

# ABX PENTRA CO2 RTU

Adults: $2 2 - 2 9 \mathrm { m m o l } / 1 .$

Reference:   
Müller-Plathe O. Acid base balance and blood gases. In: Thomas L., editor. Clinical laboratory diagnostics. 1st ed. Frankfurt: T.H.   
BooksVerlagsgesellschaft; 1998. p.318-329.

# ABX PENTRA Creatinine CP

<table><tr><td rowspan=1 colspan=2>Men</td><td rowspan=1 colspan=2>Women</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>mg/L</td></tr><tr><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.81.3</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1> mg/dL</td></tr><tr><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>106</td><td rowspan=1 colspan=1>106μmol/L</td></tr></table>

Reference:   
Tietz, N.W. Clinical guide to laboratory tests, $3 ^ { \mathrm { e m e } }$ Ed, (W.B. Saunders eds. Philadelphia USA), (1995), 186.

# ABX PENTRA Iron CP

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">ug/dl</td><td colspan="1" rowspan="1">umol/1</td></tr><tr><td colspan="1" rowspan="1">Children</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">2 weeks</td><td colspan="1" rowspan="1">63-201</td><td colspan="1" rowspan="1">11-36</td></tr><tr><td colspan="1" rowspan="1">6 months</td><td colspan="1" rowspan="1">28-135</td><td colspan="1" rowspan="1">5-24</td></tr><tr><td colspan="1" rowspan="1">12 months</td><td colspan="1" rowspan="1">35-155</td><td colspan="1" rowspan="1">6-28</td></tr><tr><td colspan="1" rowspan="1">2 - 12 years</td><td colspan="1" rowspan="1">22-135</td><td colspan="1" rowspan="1">4-24</td></tr><tr><td colspan="1" rowspan="1">Women</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">25 years</td><td colspan="1" rowspan="1">37-165</td><td colspan="1" rowspan="1">6.6-29.5</td></tr><tr><td colspan="1" rowspan="1">40 years</td><td colspan="1" rowspan="1">23-134</td><td colspan="1" rowspan="1">4.1-24.0</td></tr><tr><td colspan="1" rowspan="1">60 years</td><td colspan="1" rowspan="1">39-149</td><td colspan="1" rowspan="1">7.0-26.7</td></tr><tr><td colspan="1" rowspan="1">Pregnant Women</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">12thgestational week</td><td colspan="1" rowspan="1">42-177</td><td colspan="1" rowspan="1">7.6-31.6</td></tr><tr><td colspan="1" rowspan="1">At term</td><td colspan="1" rowspan="1">25-137</td><td colspan="1" rowspan="1">4.5-24.5</td></tr><tr><td colspan="1" rowspan="1">6 weeks postpartum</td><td colspan="1" rowspan="1">16-150</td><td colspan="1" rowspan="1">2.9-26.9</td></tr><tr><td colspan="1" rowspan="1">Men</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">25 years</td><td colspan="1" rowspan="1">40-155</td><td colspan="1" rowspan="1">7.2-27.7</td></tr><tr><td colspan="1" rowspan="1">40 years</td><td colspan="1" rowspan="1">35-168</td><td colspan="1" rowspan="1">6.3-30.1</td></tr><tr><td colspan="1" rowspan="1">60 Years</td><td colspan="1" rowspan="1">40-120</td><td colspan="1" rowspan="1">7.2-21.5</td></tr></table>

Reference: Thomas L. Clinical Laboratory Diagnostics. 1st ed. Frankfurt: THBooks Verlagsgesellschaft; 1998. p. 273-5.

# ABX PENTRA Magnesium RTU

Neonates: $1 . 2 - 2 . 6 \ : \mathrm { m g / d l }$ (0.48 - 1.05 mmol/l) Children: $1 . 5 - 2 . 3 \mathrm { m g / d l }$ (0.60 - 0.95 mmol/l) Women: 1.9 - 2.5 mg/dl (0.77 - 1.03 mmol/l) Men: $1 . 8 - 2 . 6 \mathrm { m g } / \mathrm { d l }$ (0.73 - 1.06 mmol/l)

References :

- Thomas L. Clinical Laboratory Diagnostics. $1 ^ { \mathrm { s t } }$ ed. Frankfurt: TH-Books Verlagsgesellschaft; 1998. p. 231-241.   
- Sitzmann FC. Normalwerte. München: Hans Marseille Verlag GmbH: 1986. p. 166.

# ABX PENTRA Phosphorus CP

Serum/Plasma: 27 - 45 mg/L 2.7 – 4.5 mg/dL 0.87 – 1.45 mmol/L

Reference :

Endres, D.B., Rude, R.K., Mineral and bone metabolism. Tietz Fundamentals of Clinical Chemistry, Burtis, C.A. et Ash-wood, E.R. (W.B. Saunders eds. Philadelphia USA), (2001), 795.

# ABX PENTRA Urea CP

<table><tr><td>In Serum / Plasma</td><td colspan="2">Urea</td><td>BUN</td></tr><tr><td></td><td>[mg/dl]</td><td>[mmol/1]</td><td>[mg/dl]</td></tr><tr><td>Adults:</td><td></td><td></td><td></td></tr><tr><td>Global</td><td>17-43</td><td>2.8-7.2</td><td>7.9-20.2</td></tr><tr><td>Women &lt;50 years</td><td>15-40</td><td>2.6-6.7</td><td>7.3-18.8</td></tr><tr><td>Women &gt;50 years</td><td>21-43</td><td>3.5-7.2</td><td>9.8-20.2</td></tr><tr><td>Men &lt;50 years</td><td>19-44</td><td>3.2-7.3</td><td>9.0-20.5</td></tr><tr><td>Men &gt;50 years</td><td>18-55</td><td>3.0-9.2</td><td>8.4-25.8</td></tr><tr><td>Children:</td><td></td><td></td><td></td></tr><tr><td>1-3 years</td><td>11-36</td><td>1.8-6.0</td><td>5.1-16.8</td></tr><tr><td>4-13 years</td><td>15-36</td><td>2.5-6.0</td><td>7.0-16.8</td></tr><tr><td>14-19 years</td><td>18-45</td><td>2.9-7.5</td><td>8.1-21.1</td></tr></table>

Reference:   
Thomas L. Clinical Laboratory Diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft; 1998. p. 374-377.

# ABX PENTRA Uric Acid CP

Serum, plasma: Women : 26 - 60 mg/L 2.6 - 6 mg/dL 155 – 357 µmol/l

Men : 35 - 72 mg/L 3,5 - 7,2 mg/dL 208 - 428 µmol/L

Reference : Tietz, N.W., Clinical guide to laboratory tests. 3ème Ed., (W.B.   
Saunders eds. Philadelphia USA), (1995), 268.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.